Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?

Journal of Hepatology

Volumn 64, Issue 2, 2016, Pages 262-264

  Gastaldelli, Amalia ^a   Marchesini, Giulio ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LIPID; LIRAGLUTIDE; LIVER ENZYME; LIXISENATIDE; ANTIDIABETIC AGENT; PEPTIDE;

BODY WEIGHT; DRUG EFFECT; GLUCOSE METABOLISM; HUMAN; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOTOXICITY; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NON-ALCOHOLIC FATTY LIVER DISEASE;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; NON-ALCOHOLIC FATTY LIVER DISEASE; PEPTIDES;

EID: 84954367900     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.11.031     Document Type: Editorial

References (20)

1. J.E. Campbell, and D.J. Drucker Pharmacology, physiology, and mechanisms of incretin hormone action Cell Metab 17 2013 819 837
2. G. Daniele, P. Iozzo, M. Molina-Carrion, J. Lancaster, D. Ciociaro, E. Cersosimo, and et al. Exenatide regulates cerebral glucose metabolism in brain areas associated with glucose homeostasis and reward system Diabetes 64 2015 3406 3412
3. R.L. Prigeon, S. Quddusi, B. Paty, and D.A. D'Alessio Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect Am J Physiol Endocrinol Metab 285 2003 E701 E707
4. M. Seghieri, E. Rebelos, A. Gastaldelli, B.D. Astiarraga, A. Casolaro, E. Barsotti, and et al. Direct effect of GLP-1 infusion on endogenous glucose production in humans Diabetologia 56 2013 156 161
5. X. Ding, N.K. Saxena, S. Lin, N.A. Gupta, and F.A. Anania Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Hepatology 43 2006 173 181
6. G. Svegliati-Baroni, S. Saccomanno, C. Rychlicki, L. Agostinelli, S. De Minicis, C. Candelaresi, and et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis Liver Int 31 2011 1285 1297
7. N. Panjwani, E.E. Mulvihill, C. Longuet, B. Yusta, J.E. Campbell, T.J. Brown, and et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice Endocrinology 154 2013 127 139
8. J.L. Trevaskis, P.S. Griffin, C. Wittmer, B.A. Neuschwander-Tetri, E.M. Brunt, C.S. Dolman, and et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice Am J Physiol Gastrointest Liver Physiol 302 2012 G762 G772
9. D.J. Cuthbertson, A. Irwin, C.J. Gardner, C. Daousi, T. Purewal, N. Furlong, and et al. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists PLoS One 7 2012 e50117
10. Y. Eguchi, Y. Kitajima, H. Hyogo, H. Takahashi, M. Kojima, M. Ono, and et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J) Hepatol Res 45 2015 269 278
11. N. Shao, H.Y. Kuang, M. Hao, X.Y. Gao, W.J. Lin, and W. Zou Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes Diabetes Metab Res Rev 30 2014 521 529
12. W. Tang, Q. Xu, T. Hong, G. Tong, W. Feng, S. Shen, and et al. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies Diabetes Metab Res Rev 2015 10.1002/dmrr.2713 [Epub ahead of print]
13. M.J. Armstrong, D. Hull, K. Guo, D. Barton, J.M. Hazlehurst, L.L. Gathercole, and et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatophepatitis J Hepatol 64 2016 399 408
14. M.J. Armstrong, P. Gaunt, P.A. Guruprasad, D. Barton, D. Hull, R. Parker, and et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study Lancet 2015 10.1016/S0140-6736(15)00803-X [Epub ahead of print]
15. V. Hernandez-Gea, and S.L. Friedman Pathogenesis of liver fibrosis Annu Rev Pathol 6 2011 425 456
16. K.L. Donnelly, C.I. Smith, S.J. Schwarzenberg, J. Jessurun, M.D. Boldt, and E.J. Parks Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J Clin Invest 115 2005 1343 1351
17. E. Cersosimo, A. Gastaldelli, A. Cervera, E. Wajcberg, A. Sriwijilkamol, M. Fernandez, and et al. Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects J Clin Endocrinol Metab 96 2011 1763 1770
18. E.M. Koehler, E.P. Plompen, J.N. Schouten, B.E. Hansen, S. Darwish Murad, P. Taimr, and et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study Hepatology 2015 10.1002/hep.27981 [Epub ahead of print]
19. G. Marchesini, N. Mazzella, and G. Forlani Weight loss for a healthy liver Gastroenterology 149 2015 274 278
20. V. Ratziu, Z. Goodman, and A. Sanyal Current efforts and trends in the treatment of NASH J Hepatol 62 2015 S65 S75